Priothera

Priothera Ltd is a clinical-stage biotechnology company based in Dublin, Ireland, with an additional location in Saint Louis, France. Founded in 2020, Priothera specializes in the development of orally administered sphingosine 1 phosphate (S1P) receptor modulators aimed at treating haematological malignancies. The company's leading candidate, mocravimod, is designed to reduce the egress of T cell subsets from lymphatic tissue, thereby enhancing the curative potential of allogeneic hematopoietic stem cell transplantation. By providing dual inhibition of graft versus host disease while promoting graft versus leukemia effects, Priothera aims to significantly improve outcomes for patients undergoing such transplants.